Building a future with values, quality and innovation.

Our Company

Professionals committed to finding solutions conducive to the improvement of people's lives.

We are dedicated to the production, distribution and sale of pharmaceuticals for the treatment of rare, hereditary, degenerative and low-prevalence diseases.

We started out in 2013 with the mission of supplying high-quality products to the region and helping out both patients and members of the medical staff. It is our belief that creating value in everything that we do is essential to succeed in enhancing the quality of life of all persons.

Khairi Pharmaceuticals, solutions for complex therapies.

Strategic Pillars

Products

Focused on oncology, hematology and rare diseases.

PORTFOLIO (PDF)
  • Capecitabina

    Capecitabine

    Film-coated Tablets

    Indicated for the first-line treatment of advanced gastric cancer in combination with platinum-based chemotherapy.

    Indicated as monotherapy in the adjuvant treatment of patients suffering from Dukes C (stage III) colon cancer, after the full surgical resection of the primary tumor.

    MORE INFO
  • Imatinib

    Imatinib

    Film-coated Tablets

    Adult and pediatric patients with Chronic Myeloid Leukemia (CML), recently diagnosed positive Philadelphia chromosome (Ph+) or BCR/ABL fusion gene, for which bone-marrow replacement has not been considered as a first-line treatment.

    Adult and pediatric patients with chronic-stage CML Ph+ after failed treatment with alpha-interferon, or in accelerated phase or blast crisis.

    MORE INFO
  • Pemetrexed

    Pemetrexed

    Lyophilized powder

    Indicated in combination with cisplatin for the treatment of patients with unresectable malignant pleural mesothelioma who had not received chemotherapy before, and as a first line treatment of patients with locally advanced or metastatic non-small cell lung cancer, except for those who have a predominant squamous cell histology.

    Indicated as monotherapy in maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer.

    MORE INFO
  • Abiraterona

    Abiraterone Acetate

    Film-coated Tablets

    Indicated concomitantly with Prednisone or Prednisolone for the treatment of metastatic castration-resistant prostate cancer in asymptomatic or mildly symptomatic adult men after failure of androgen deprivation therapy in which chemotherapy is not clinically indicated; metastatic castration-resistant prostate cancer in adult men whose disease has progressed during or after a docetaxel-based chemotherapy regime.

    MORE INFO
  • Pazopanib

    Pazopanib

    Film-coated Tablets

    Indicated for the first line treatment of adult patients with advanced Renal Cell Carcinoma (RCC) and in patients with advanced disease who have received prior treatment with cytokines.

    Also indicated for the treatment of adult patients with certain types of advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy for metastatic disease, or progressed after 12 months of adjuvant/neoadjuvant treatment.

    MORE INFO
  • Bendamustine

    Bendamustine

    Lyophilized powder

    Indicated as first-line treatment of patients with chronic lymphocytic leukemia (Binet stage B or C) when combination therapy with fludarabine is not suitable.

    Indicated as monotherapy for the treatment of patients with indolent non-Hodgkin Lymphoma that has progressed during or within the six-month rituximab treatment or with a regime containing rituximab.

    MORE INFO
  • Lenalidomida

    Lenalidomide

    Hard Capsules

    Transfusion-dependent anemia in low- or medium-risk Myelodysplastic Syndrome (MDS), associated with 5q deletion, with or without other additional cytogenetic abnormalities.

    Multiple Myeloma relapsed or resistant to a previous line of treatment, in association with Dexamethasone.

    MORE INFO
  • Imatinib

    Imatinib

    Film-coated Tablets

    Adult and pediatric patients with Chronic Myeloid Leukemia (CML), recently diagnosed positive Philadelphia chromosome (Ph+) or BCR/ABL fusion gene, for which bone-marrow replacement has not been considered as a first-line treatment.

    Adult and pediatric patients with chronic-stage CML Ph+ after failed treatment with alpha-interferon, or in accelerated phase or blast crisis.

    MORE INFO
  • Bortezomib

    Bortezomib

    Lyophilized powder

    Indicated for the treatment of adult patients with multiple myeloma.

    Indicated also for the treatment of adult patients with mantle cell lymphoma.

    MORE INFO
  • Wilfactin

    Wilfactin

    Lyophilized powder

    Indicated for the treatment and prevention of hemorrhagic episodes and during surgery in von Willebrand's disease. WILFACTIN is used when treatment with desmopressin alone, another medication, is ineffective or contraindicated..

    MORE INFO
  • Pirfenidone

    Pirfenidone

    Film-coated Tablets

    Indicated for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) in adults. MORE INFO

  • Glassia

    Glassia

    Solution for infusion

    Indicated for chronic augmentation and maintenance therapy in individuals with clinically evident emphysema due to severe hereditary deficiency alpha1-PI, also known as alpha-1-antitrypsin (AAT) deficiency.

    MORE INFO
  • Fingolimod

    Fingolimod

    Hard Capsules

    Indicated in adults patients with Relapsing- Remitting Multiple Sclerosis (MS), which occurs with outbreaks, particularly in: Patients who do not respond to treatment despite a treatment for MS or patients who rapidly develop severe MS.

    MORE INFO
  • Terflimida

    Teriflunomide

    Film-coated Tablets

    Indicated for the treatment of adult patients with relapsing remitting Multiple Sclerosis (MS).

    MORE INFO
  • Tenalcet

    Cinacalcet

    Film-coated Tablets

    Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease on dialysis. It can be used as part of a therapeutic regimen, which includes phosphate binders and/or vitamin D analogues, as appropriate.

    Hypercalcemia in adult patients with primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but it is not clinically adequate or contraindicated.

    MORE INFO
treatm

Partners

We are inviting you to be our partner in the region in providing solutions for complex therapies.

Open-mindedness and innovation

New drugs for the treatment of different disorders are discovered and approved every day. However, making these drugs available and securing patient access to new treatments means a great challenge. Partnering with companies willing to introduce their products to our region is a key objective of ours and an essential part of our strategy.

We are flexible and understand that adapting to new business scenarios will make it easier for international companies to access our regional markets.

What we offer

The complexity of processes for product registration and marketing in emerging markets requires seeking out local partners capable of making things happen. Khairi’s experience and knowledge of the regional market makes it possible to import complex-therapy products into the region.

Through Khairi’s network and subsidiaries you will be able to extend your coverage and improve your results.

Who

Shared visions, strategies, goals and dreams are essential toward concluding durable and sustainable agreements.

Low-prevalence diseases are generally chronic and degenerative. Improving the quality of life of patients and their environment is a key component of our mission. The companies who share the same goals will empathize with Khairi and succeed in reaching fruitful agreements for the registration and marketing of their products.

Transparency and commitment, these are the values that inspire us.

CONTACT US

Our Partners

Contact

SEND

Our Offices

Uruguay

Parque de las Ciencias
Ruta 101, Km 23,500, Edificio 101, Piso 2
Canelones, Uruguay

Phone/Fax: +598 2683 8579

Paraguay

Avda. Aviadores del Chaco 2050,
Edif.World Trade Center Asunción
Torre 3 Piso 16 Of.A
Asunción, Paraguay

Phone/Fax: +595 972123714